Materials and methods for delivering compositions to selected tissues

Patent metadata

Field	Value
Publication number	US-2016338960-A1
Application number	US-201615004790-A
Country	US
Kind code	A1
Filing date	Jan 22, 2016
Priority date	Apr 16, 2007
Publication date	Nov 24, 2016
Grant date	—

Abstract

This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.

First claim

1 - 61 . (canceled)

62 . A method of preparing a composition for controlled drug delivery comprising:
providing a porous silicon film; heating the porous silicon film in an oxidizing environment at a temperature above 600° C.; preparing particles from the oxidized porous silicon film; and treating the oxidized porous silicon particles with a drug or biologically active material.

63 . The method of claim 62 , wherein the particles have a size of between about 0.1 μm and about 100 μm.

64 . The method of claim 62 , wherein the porous silicon film comprises pores with a free volume of from 50% to 80%.

65 . The method of claim 62 , wherein the drug or biologically active material is a protein.

66 . The method of claim 65 , wherein the drug or biologically active material is bevacizumab, ranibizumab, or pegaptanib.

67 . The method of claim 62 , wherein the drug of biologically active material is selected from the group consisting of angiostatic steroids, metalloproteinase inhibitors, VEGF binding drugs, PEDF, an 8-mer peptide fragment of urokinase (uPA), and dexamethasone.

68 . The method of claim 62 , wherein the drug or biologically active material targets a disease or disorder of the eye.

69 . The method of claim 68 , wherein the disease or disorder of the eye is selected from the group consisting of: age-related macular degeneration (AMD), choroidal neovascularization (CNV), uveitis, diabetic retinopathy, retinovasclar disease, retinal detachment (PVR), and glaucoma.

70 . The method of claim 62 , wherein the porous silicon film comprises a layered nanostructure.

71 . The method of claim 62 , comprising the step of heating the porous silicon film in an oxidizing environment at a temperature above 700° C.

72 . The method of claim 62 , comprising the step of heating the porous silicon film in an oxidizing environment at a temperature above 800° C.

73 . The method of claim 62 , wherein particles are prepared from the oxidized porous silicon film after the porous silicon film is heated in an oxidizing environment at a temperature above 600° C.

74 . The method of claim 62 , wherein the porous silicon film comprises pores selectively dimensioned to obtain a desired reflective wavelength.

75 . The method of claim 62 , further comprising the step of capping the porous silicon film with a polymeric material.

76 . The method of claim 62 , wherein the porous silicon film comprises pores configured to enhance binding efficacy of the drug or biologically active material.

Assignees

• Univ California
• Univ California

Inventors

• Freeman William R
• Sailor Michael J
• Cheng Lingyun

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/06

  Antiarrhythmics · CPC title